China-based Fosun Pharma has received breakthrough therapy designation (BTD) from Saudi Arabia's Food and Drug Authority (SFDA) for its MEK 1/2 inhibitor luvometinib in adult Langerhans cell histiocytosis (LCH) and histiocytic neoplasms. The designation accelerates regulatory review to 60 working days post-submission, based on clinical data showing superior efficacy and safety versus existing treatments. Luvometinib is China's only approved therapy for both adult LCH and paediatric neurofibromatosis type 1 (NF1), with marketing authorisations granted in 2024.

The oral therapy selectively inhibits aberrant MAPK pathway activation driving tumour proliferation in these rare diseases. Fosun has established commercial networks across the US, Europe and MENAT regions, including a strategic partnership with Saudi Arabia's Fakeeh Care Group. The company's 1000-member global team will drive luvometinib's Middle East launch following recent approvals in China for LCH and NF1 indications.

According to PharmCube's NextBiopharm® database, 17 MEK 1/2 inhibitors are being actively developed worldwide in nearly two dozen diseases. Click here to request a free trial for NextBiopharm®.